FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.
Formulary Watch
Latest News
All News
Advertisement
FDA approved Yondelis (trabectedin), by Janssen Biotech for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.
FDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
Sarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.
The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.
FDA has approved talimogene laherparepvec (Imlygic, Amgen) for the treatment of unresectable melanoma lesions.
Deaths from drug overdoses are the leading cause of injury death in the United States, ahead of deaths linked to motor vehicles and firearms, according to the new 2015 National Drug Threat Assessment (NDTA), released by the Drug Enforcement Administration.
Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside conference, November 12-14 in Washington D.C.
After Valeant and Express Scripts cut ties with mail order specialty pharmacy Philidor Rx Services, the company said it would be closing.
Advertisement
Advancements in IV robotics are mitigating the risks of human error in the compounding process. The misconceptions of IV robotics are many, but there are also many real world examples of how hospitals and health systems are improving processes by implementing technology to support in-house sterile compounding.
FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
The FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.
A new online library or knowledge portal, the Type 2 Diabetes Genetics Beta, has been launched to provide open-access searching of genetic and clinical information on type 2 diabetes.
A pharmacist-led telemonitoring program reduced blood sugar levels in diabetics, according to a new study.
FDA has approved buprenorphine (Belbuca, Endo Pharmaceuticals) buccal film for use in patients with chronic pain.
FDA has approved idarucizumab (Praxbind, Boehringer Ingelheim) as the first reversal agent for Pradaxa.
When two new treatments for idiopathic pulmonary fibrosis (IPF) were approved by FDA last year, there was not much data available on the drugs in patient populations.
The FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
FDA approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
FDA approved patiromer (Veltassa, Relypsa) oral suspension for the treatment of hyperkalemia. Hyperkalemia is the condition when blood potassium levels are higher than normal in the kidneys, which can lead to abnormal heart rhythms or sometimes death.
FDA approved meloxicam (Vivlodex, Iroko Pharmaceuticals, LLC) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain in 5-mg and 10-mg doses administered once daily.
The FDA this week approved Coagadex, Coagulation Factor X (Human) for hereditary Factor X (10) deficiency. Until the new orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency.
Laboratory diagnostics are essential tools of physician practice, informing many medical decisions. Physicians will increasingly rely on companion and other types of lab diagnostics that consider genetic, proteomic, or other markers in connection with drug treatment strategies.
Pain management is a problem for patients, practitioners, pharmacists, and others. Many patients are not getting the care and relief they deserve, even when they suffer from acute or chronic pain. In this blog post, Srinivas Nalamachu, MD asks if its possible to balance patient access to pain medication with safety and economic value.
The CEO of Valeant Pharmaceuticals, which is being investigated by the government for raising drug prices, predicted more modest price increases ahead for the pharmaceutical industry.
Advertisement
Advertisement